Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company

Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025

Second discovery partnership in obesity initiated

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced it has secured $65 million in Series B funding from investors including Ampersand's founder, Flagship Pioneering, Eli Lilly & Company, and several additional new investors. In addition, the company announced the advancement of two lead programs and a second discovery partnership in obesity.

Ampersand's Series B funding will fuel the continued development of its computationally powered Address, Navigate, Determine (AND)™ Platform to program AND-Body™ Therapeutics, a new category of smarter biologic medicines. AND-Body Therapeutics are designed to localize to their intended target and conditionally actuate biology to treat disease, enabling improved target engagement while limiting on-target, off-tissue side effects. The versatility of the AND Platform allows Ampersand to take aim at a broad range of diseases ...